Huatai-Pinebridge Fund Management Co., Ltd - Hang Seng Innovative Drug ETF (SHA:520500)

Assets	n/a
Expense Ratio	0.60%
PE Ratio	29.26
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a
1-Year Return	-27.45%

Volume	1,009,308,700
Open	1.439
Previous Close	1.430
Day's Range	1.431 - 1.457
52-Week Low	1.155
52-Week High	2.040
Beta	n/a
Holdings	42
Inception Date	Dec 16, 2024

About 520500

520500.SS was created on 2024-12-16 by Huatai. The fund's investment portfolio concentrates primarily on health care equity. Closely track the performance of the underlying index and seek to minimize tracking deviation and tracking error.

• Asset Class: Equity
• Category: Health Care
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 520500
• Provider: Huatai
• Index Tracked: Hang Seng Innovative Drug

Performance

520500 had a total return of -27.45% in the past year, including dividends. Since the fund's inception, the average annual return has been 22.32%.

Top 10 Holdings

70.47% of assets

Name	Symbol	Weight
Innovent Biologics, Inc.	1801	10.46%
BeOne Medicines AG	6160	10.46%
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	6990	9.58%
Akeso, Inc.	9926	8.57%
Sino Biopharmaceutical Limited	1177	7.61%
RemeGen Co., Ltd.	9995	5.73%
Duality Biotherapeutics, Inc.	9606	5.54%
CSPC Pharmaceutical Group Limited	1093	5.03%
3SBio Inc.	1530	4.16%
InnoCare Pharma Limited	9969	3.33%

Data Sources: S&P Global Market Intelligence and Finnhub

Historical data is provided by S&P Global Market Intelligence. Several fund data points are also provided by Finnhub.

Last checked:

Sep 23, 2026

Data Sources Report a data error